Price
CHART BY
Frequently asked questions
What is Ventyx's market capitalization?
The market capitalization of Ventyx is $990.87M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Ventyx?
Ventyx's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.50. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Ventyx's stock?
Currently, 9 analysts cover Ventyx's stock, with a consensus target price of $13.38. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Ventyx?
Ventyx's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$115.10M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Ventyx?
Ventyx has a free cash flow of -$87.87M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Ventyx have, and what sector and industry does it belong to?
Ventyx employs approximately 82 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Ventyx's shares?
The free float of Ventyx is 64.33M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $990.87M
- EPS (TTM)
- -$1.50
- Free Float
- 64.33M
- EBITDA (TTM)
- -$115.10M
- Free Cashflow (TTM)
- -$87.87M
Pricing
- 52W span
- $0.783$25.00
Analyst Ratings
The price target is $13.38 and the stock is covered by 9 analysts.
Buy
0
Hold
9
Sell
0
Information
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.
- Employees
- 82
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- VTYX
Fundamentals & EOD data from FactSet